Hypoglycemia surgery

Revision as of 14:48, 17 November 2017 by Mehdi Pahlavani (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Hypoglycemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoglycemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoglycemia surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoglycemia surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoglycemia surgery

CDC on Hypoglycemia surgery

Hypoglycemia surgery in the news

Blogs on Hypoglycemia surgery

Directions to Hospitals Treating Hypoglycemia

Risk calculators and risk factors for Hypoglycemia surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Surgical treatment is reserved for insulinoma. Surgical removal of the insulinoma is the treatment of choice and resection of metastatic liver disease.

Surgery

Surgical treatment is reserved for the cases where the cause of hypoglycemia is insulinoma.

  • Surgical removal of the insulinoma is the treatment of choice:[1]
  • Recurrence is more common in the patients with MEN1.
  • Hepatic resection is indicated for the treatment of metastatic liver disease if the general condition is good. Resection should be considered only for patients with a limited number of hepatic metastases.[4]

References

  1. Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin Proc. 66 (7): 711–9. PMID 1677058.
  2. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y; et al. (2013). "Diagnosis and management of insulinoma". World J Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
  3. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH (1991). "Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach". Surgery. 110 (6): 998–1004, discussion 1004-5. PMID 1684067.
  4. Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A; et al. (2002). "Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure". J Am Coll Surg. 194 (6): 761–4. PMID 12081066.